2023-12-05 07:46:05
Zurich (awp) – The Swiss stock market was preparing to move forward on Tuesday, notwithstanding a slowdown in the American indices on Monday evening. “Hangover,” summarizes Ipek Ozkardeskaya, for the online bank Swissquote. “Markets have priced in an unreasonable number of rate cuts from the Federal Reserve (Fed) for next year, assuming a soft landing for the economy,” continues the analyst.
“Today it is the Bank of Australia which will meet, but we will also learn regarding producer prices in the euro zone (October), the final PMIs for November in the euro zone and the United States, as well as the October JOLTS employment report”, lists John Plassard, of Mirabaud Banque, in a comment.
At 08:10, the pre-SMI extrapolated by Julius Bär rose by 0.19% to 10,973.61 points, on a broad green front, following having closed the day before up by 0.60%.
The registered UBS (-1.3%) was the only unfortunate exception, without any particular indication.
The good Roche (+1.1%) occupied the other end of the ranking. The Rhine laboratory claims clinical success in the field of breast cancer with experimental inavolisib, in combination with Ibrance (palbociclib) from competitor Pfizer and fulverstrant, which has fallen into the public domain.
The other star stocks were covered by 0.1% to 0.2%.
At the SLI, the dental industry equipment manufacturer Straumann dropped 1.3%, handicapped by a downgrading of recommendation from JPMorgan to “neutral”.
On the broader market, Dormakaba (+0.1%) has just announced a handover at the top of its management.
jh/al
1701762776
#Zurich #Stock #Exchange #insensitive #gloom #Wall #Street #December
